Randomized, Open-Label, Parallel Group Study To Investigate The Safety And Tolerability Of Multiple Dose Lersivirine (Proposed Phase 3 Formulation) For 21 Days In Healthy Subjects.

Trial Profile

Randomized, Open-Label, Parallel Group Study To Investigate The Safety And Tolerability Of Multiple Dose Lersivirine (Proposed Phase 3 Formulation) For 21 Days In Healthy Subjects.

Completed
Phase of Trial: Phase I

Latest Information Update: 16 May 2011

At a glance

  • Drugs Lersivirine (Primary)
  • Indications HIV infections
  • Focus Adverse reactions
  • Most Recent Events

    • 16 May 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 12 May 2011 Planned End Date changed from 1 Apr 2011 to 1 May 2011 as reported by ClinicalTrials.gov.
    • 20 Apr 2011 Planned End Date changed from 1 Mar 2011 to 1 Apr 2011, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top